Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

Cross-linker-mediated regulation of actin network organization controls tissue morphogenesis.

Krueger D, Quinkler T, Mortensen SA, Sachse C, De Renzis S.

J Cell Biol. 2019 Aug 5;218(8):2743-2761. doi: 10.1083/jcb.201811127. Epub 2019 Jun 28.

2.

The SSRP1 subunit of the histone chaperone FACT is required for seed dormancy in Arabidopsis.

Michl-Holzinger P, Mortensen SA, Grasser KD.

J Plant Physiol. 2019 May;236:105-108. doi: 10.1016/j.jplph.2019.03.006. Epub 2019 Mar 26.

PMID:
30947026
3.

Models of the complement C1 complex.

Mortensen SA, Sander B, Jensen RK, Pedersen JS, Golas MM, Thiel S, Andersen GR.

Proc Natl Acad Sci U S A. 2018 Apr 24;115(17):E3866. doi: 10.1073/pnas.1803577115. Epub 2018 Apr 13. No abstract available.

4.

Reply to Arlaud et al.: Structure of the C1 complex and the unbound C1r2s2 tetramer.

Mortensen SA, Sander B, Jensen RK, Pedersen JS, Golas M, Jensenius JC, Hansen AG, Thiel S, Andersen GR.

Proc Natl Acad Sci U S A. 2017 Jul 18;114(29):E5768-E5770. doi: 10.1073/pnas.1704353114. Epub 2017 Jul 12. No abstract available.

5.

The Composition of the Arabidopsis RNA Polymerase II Transcript Elongation Complex Reveals the Interplay between Elongation and mRNA Processing Factors.

Antosz W, Pfab A, Ehrnsberger HF, Holzinger P, Köllen K, Mortensen SA, Bruckmann A, Schubert T, Längst G, Griesenbeck J, Schubert V, Grasser M, Grasser KD.

Plant Cell. 2017 Apr;29(4):854-870. doi: 10.1105/tpc.16.00735. Epub 2017 Mar 28.

6.

Endogenous Natural Complement Inhibitor Regulates Cardiac Development.

Mortensen SA, Skov LL, Kjaer-Sorensen K, Hansen AG, Hansen S, Dagnæs-Hansen F, Jensenius JC, Oxvig C, Thiel S, Degn SE.

J Immunol. 2017 Apr 15;198(8):3118-3126. doi: 10.4049/jimmunol.1601958. Epub 2017 Mar 3.

7.

Structure and activation of C1, the complex initiating the classical pathway of the complement cascade.

Mortensen SA, Sander B, Jensen RK, Pedersen JS, Golas MM, Jensenius JC, Hansen AG, Thiel S, Andersen GR.

Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):986-991. doi: 10.1073/pnas.1616998114. Epub 2017 Jan 19.

8.

Coenzyme Q10: will this natural substance become a guideline-directed adjunctive therapy in heart failure?

Mortensen SA.

JACC Heart Fail. 2015 Mar;3(3):270-1. doi: 10.1016/j.jchf.2014.12.006. No abstract available.

9.

The mitochondria in heart failure: a target for coenzyme Q10 therapy?

Mortensen SA, Mortensen AL.

Clin Pharmacol Ther. 2014 Dec;96(6):645-7. doi: 10.1038/clpt.2014.175. No abstract available.

PMID:
25399710
10.

The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial.

Mortensen SA, Rosenfeldt F, Kumar A, Dolliner P, Filipiak KJ, Pella D, Alehagen U, Steurer G, Littarru GP; Q-SYMBIO Study Investigators.

JACC Heart Fail. 2014 Dec;2(6):641-9. doi: 10.1016/j.jchf.2014.06.008. Epub 2014 Oct 1.

11.

Structural insights into the mechanism of negative regulation of single-box high mobility group proteins by the acidic tail domain.

Stott K, Watson M, Bostock MJ, Mortensen SA, Travers A, Grasser KD, Thomas JO.

J Biol Chem. 2014 Oct 24;289(43):29817-26. doi: 10.1074/jbc.M114.591115. Epub 2014 Sep 4.

12.

The seed dormancy defect of Arabidopsis mutants lacking the transcript elongation factor TFIIS is caused by reduced expression of the DOG1 gene.

Mortensen SA, Grasser KD.

FEBS Lett. 2014 Jan 3;588(1):47-51. doi: 10.1016/j.febslet.2013.10.047. Epub 2013 Nov 16.

13.

Virtual histology assessment of cardiac allograft vasculopathy following introduction of everolimus--results of a multicenter trial.

Arora S, Erikstad I, Ueland T, Sigurdardottir V, Ekmehag B, Jansson K, Eiskjaer H, Bøtker HE, Mortensen SA, Saunamaki K, Gude E, Ragnarsson A, Solbu D, Aukrust P, Gullestad L.

Am J Transplant. 2012 Oct;12(10):2700-9. doi: 10.1111/j.1600-6143.2012.04234.x. Epub 2012 Sep 7.

14.

Plant proteins containing high mobility group box DNA-binding domains modulate different nuclear processes.

Antosch M, Mortensen SA, Grasser KD.

Plant Physiol. 2012 Jul;159(3):875-83. doi: 10.1104/pp.112.198283. Epub 2012 May 14. Review. No abstract available.

15.

Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: the significance of baseline glomerular filtration rate.

Arora S, Gude E, Sigurdardottir V, Mortensen SA, Eiskjær H, Riise G, Mared L, Bjørtuft O, Ekmehag B, Jansson K, Simonsen S, Aukrust P, Solbu D, Iversen M, Gullestad L.

J Heart Lung Transplant. 2012 Mar;31(3):259-65. doi: 10.1016/j.healun.2011.12.010.

PMID:
22333403
16.

Good long-term survival after paediatric heart transplantation.

Kruse CD, Helvind M, Jensen T, Gustafsson F, Mortensen SA, Andersen HO.

Dan Med J. 2012 Jan;59(1):A4367.

PMID:
22239842
17.

Rapid decline in glomerular filtration rate during the first weeks following heart transplantation.

Hornum M, Andersen M, Gustafsson F, Oturai P, Sander K, Mortensen SA, Feldt-Rasmussen B.

Transplant Proc. 2011 Jun;43(5):1904-7. doi: 10.1016/j.transproceed.2011.02.065.

PMID:
21693298
18.

Effect of everolimus introduction on cardiac allograft vasculopathy--results of a randomized, multicenter trial.

Arora S, Ueland T, Wennerblom B, Sigurdadottir V, Eiskjær H, Bøtker HE, Ekmehag B, Jansson K, Mortensen SA, Saunamaki K, Simonsen S, Gude E, Bendz B, Solbu D, Aukrust P, Gullestad L.

Transplantation. 2011 Jul 27;92(2):235-43. doi: 10.1097/TP.0b013e31822057f1.

PMID:
21677600
19.

Reduced expression of the DOG1 gene in Arabidopsis mutant seeds lacking the transcript elongation factor TFIIS.

Mortensen SA, Sønderkær M, Lynggaard C, Grasser M, Nielsen KL, Grasser KD.

FEBS Lett. 2011 Jun 23;585(12):1929-33. doi: 10.1016/j.febslet.2011.04.077. Epub 2011 May 8.

20.

Driveline infections in patients supported with a HeartMate II: incidence, aetiology and outcome.

Bomholt T, Moser C, Sander K, Boesgaard S, Køber L, Olsen PS, Hansen PB, Mortensen SA, Gustafsson F.

Scand Cardiovasc J. 2011 Oct;45(5):273-8. doi: 10.3109/14017431.2011.577236. Epub 2011 May 4.

PMID:
21539474
21.

Low coenzyme Q₁₀ levels and the outcome of statin treatment in heart failure.

Mortensen SA.

J Am Coll Cardiol. 2011 Apr 5;57(14):1569; author reply 1569. doi: 10.1016/j.jacc.2010.10.051. No abstract available.

22.

Factors associated with the development of cytomegalovirus infection following solid organ transplantation.

da Cunha-Bang C, Sørensen SS, Iversen M, Sengeløv H, Hillingsø JG, Rasmussen A, Mortensen SA, Fox ZV, Kirkby NS, Christiansen CB, Lundgren JD.

Scand J Infect Dis. 2011 May;43(5):360-5. doi: 10.3109/00365548.2010.549836. Epub 2011 Feb 9.

PMID:
21306196
23.

Regarding: Humar et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010;10:1228–1237.

da Cunha-Bang C, Iversen M, Mortensen SA, Rasmussen A, Sengeløv H, Sørensen SS, Lundgren J.

Am J Transplant. 2011 Feb;11(2):408. doi: 10.1111/j.1600-6143.2010.03349.x. Epub 2011 Jan 10. No abstract available.

24.

Two-year outcomes in thoracic transplant recipients after conversion to everolimus with reduced calcineurin inhibitor within a multicenter, open-label, randomized trial.

Gullestad L, Mortensen SA, Eiskjær H, Riise GC, Mared L, Bjørtuft O, Ekmehag B, Jansson K, Simonsen S, Gude E, Rundqvist B, Fagertun HE, Solbu D, Iversen M.

Transplantation. 2010 Dec 27;90(12):1581-9. doi: 10.1097/TP.0b013e3181fd01b7.

PMID:
21030905
25.

Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial.

Gullestad L, Iversen M, Mortensen SA, Eiskjaer H, Riise GC, Mared L, Bjørtuft O, Ekmehag B, Jansson K, Simonsen S, Gude E, Rundqvist B, Fagertun HE, Solbu D, Bergh CH.

Transplantation. 2010 Apr 15;89(7):864-72. doi: 10.1097/TP.0b013e3181cbac2d.

PMID:
20061999
26.

Primary cardiac tumors: a clinicopathologic evaluation of four cases.

Winther C, Timmermans-Wielenga V, Daugaard S, Mortensen SA, Sander K, Andersen CB.

Cardiovasc Pathol. 2011 Jan-Feb;20(1):63-7. doi: 10.1016/j.carpath.2009.11.004. Epub 2010 Jan 8.

PMID:
20060324
27.

Severely impaired von Willebrand factor-dependent platelet aggregation in patients with a continuous-flow left ventricular assist device (HeartMate II).

Klovaite J, Gustafsson F, Mortensen SA, Sander K, Nielsen LB.

J Am Coll Cardiol. 2009 Jun 9;53(23):2162-7. doi: 10.1016/j.jacc.2009.02.048.

28.

Cardiac sarcoidosis and heart transplantation: a report of four consecutive patients.

Milman N, Andersen CB, Mortensen SA, Sander K.

Sarcoidosis Vasc Diffuse Lung Dis. 2008 Sep;25(1):51-9.

PMID:
19070261
29.

[The Mechanical Heart--HeartMate 1--Danish results].

Sander K, Andersen CB, Boesgaard S, Eliasen KR, Gustafsson F, Hansen PB, Mortensen SA, Olsen PS.

Ugeskr Laeger. 2007 Sep 24;169(39):3290-4. Danish.

PMID:
17953888
30.

[Destination therapy in end-stage heart failure. A possible alternative to heart transplantation?].

Olsen PS, Sander K, Hansen PB, Mortensen SA, Gustafsson F, Boesgaard S.

Ugeskr Laeger. 2007 Sep 24;169(39):3287-9. Danish.

PMID:
17953887
31.

Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance.

Campistol JM, Albanell J, Arns W, Boletis I, Dantal J, de Fijter JW, Mortensen SA, Neumayer HH, Øyen O, Pascual J, Pohanka E, Schena FP, Serón D, Sparacino V, Chapman JR.

Nephrol Dial Transplant. 2007 May;22 Suppl 1:i36-41. Review.

PMID:
17456617
32.

[Cardiac sarcoidosis--a difficult diagnosis. A report of 8 consecutive patients with arrhythmias and cardiomyopathy].

Milman N, Andersen CB, Mortensen SA.

Ugeskr Laeger. 2006 Oct 30;168(44):3822-4. Danish.

PMID:
17118243
33.

[Cardiac sarcoidosis].

Milman N, Mortensen SA.

Ugeskr Laeger. 2006 Oct 30;168(44):3801-6. Review. Danish.

PMID:
17118237
34.

Induction therapy after cardiac transplantation: a comparison of anti-thymocyte globulin and daclizumab in the prevention of acute rejection.

Carlsen J, Johansen M, Boesgaard S, Andersen CB, Arendrup H, Aldershvilet J, Mortensen SA.

J Heart Lung Transplant. 2005 Mar;24(3):296-302.

PMID:
15737756
35.

Serum coenzyme Q10 concentrations in healthy men supplemented with 30 mg or 100 mg coenzyme Q10 for two months in a randomised controlled study.

Zita C, Overvad K, Mortensen SA, Sindberg CD, Moesgaard S, Hunter DA.

Biofactors. 2003;18(1-4):185-93.

PMID:
14695934
37.

Substantial species differences in relation to formation and degradation of N-acyl-ethanolamine phospholipids in heart tissue: an enzyme activity study.

Moesgaard B, Petersen G, Mortensen SA, Hansen HS.

Comp Biochem Physiol B Biochem Mol Biol. 2002 Mar;131(3):475-82.

PMID:
11959029
38.

Temporal changes in myocardial endothelial nitric oxide synthase expression following human heart transplantation.

Vejlstrup NG, Andersen CB, Boesgaard S, Mortensen SA, Aldershvile J.

J Heart Lung Transplant. 2002 Feb;21(2):211-6.

PMID:
11834349
39.

Cerebral blood flow in patients with chronic heart failure before and after heart transplantation.

Gruhn N, Larsen FS, Boesgaard S, Knudsen GM, Mortensen SA, Thomsen G, Aldershvile J.

Stroke. 2001 Nov;32(11):2530-3.

PMID:
11692012
40.

Macrophage and lymphocyte chimerism in bronchoalveolar lavage cells from human lung allograft recipients.

Wiebe BM, Mortensen SA, Petterson G, Svendsen UG, Andersen CB.

APMIS. 2001 Jun;109(6):435-40.

PMID:
11506475
41.

[Cardiogenic shock in acute myocardial infarction. Time for a more aggressive therapeutic strategy?].

Boesgaard S, Wanscher MC, Sander KM, Mortensen SA, Aldershvile J.

Ugeskr Laeger. 2000 Oct 30;162(44):5901-5. Review. Danish.

PMID:
11094548
42.

[Heart transplantation].

Mortensen SA, Boesgaard S, Arendrup HC, Andersen LW, Aldershvile J.

Ugeskr Laeger. 2000 Oct 30;162(44):5895-900. Review. Danish.

PMID:
11094547
43.

Myocardial perfusion scintigraphy as a screening method for significant coronary artery stenosis in cardiac transplant recipients.

Carlsen J, Toft JC, Mortensen SA, Arendrup H, Aldershvile J, Hesse B.

J Heart Lung Transplant. 2000 Sep;19(9):873-8.

PMID:
11008077
44.

[Circulatory support with the mechanical heart, "HeartMate"].

Sander Jensen KM, Aldershvile J, Boesgaard S, Hansen PB, Kjersem AM, Kolbye A, Mortensen SA, Nielsen KS, Olsen PS, Rasmussen B, Vogelsang G.

Ugeskr Laeger. 2000 Jun 26;162(26):3717-22. Review. Danish.

PMID:
10925631
45.

Coenzyme Q10 as an adjunctive therapy in patients with congestive heart failure.

Mortensen SA.

J Am Coll Cardiol. 2000 Jul;36(1):304-5. No abstract available.

46.

Coenzyme Q10 in health and disease.

Overvad K, Diamant B, Holm L, Holmer G, Mortensen SA, Stender S.

Eur J Clin Nutr. 1999 Oct;53(10):764-70. Review.

PMID:
10556981
47.

High serum coenzyme Q10, positively correlated with age, selenium and cholesterol, in Inuit of Greenland. A pilot study.

Pedersen HS, Mortensen SA, Rohde M, Deguchi Y, Mulvad G, Bjerregaard P, Hansen JC.

Biofactors. 1999;9(2-4):319-23.

PMID:
10416047
48.

The effect of coenzyme Q10 administration on metabolic control in patients with type 2 diabetes mellitus.

Eriksson JG, Forsén TJ, Mortensen SA, Rohde M.

Biofactors. 1999;9(2-4):315-8.

PMID:
10416046
49.

No effect of antioxidant supplementation in triathletes on maximal oxygen uptake, 31P-NMRS detected muscle energy metabolism and muscle fatigue.

Nielsen AN, Mizuno M, Ratkevicius A, Mohr T, Rohde M, Mortensen SA, Quistorff B.

Int J Sports Med. 1999 Apr;20(3):154-8.

PMID:
10333091
50.

Impact of ubiquinone (coenzyme Q10) treatment on glycaemic control, insulin requirement and well-being in patients with Type 1 diabetes mellitus.

Henriksen JE, Andersen CB, Hother-Nielsen O, Vaag A, Mortensen SA, Beck-Nielsen H.

Diabet Med. 1999 Apr;16(4):312-8.

PMID:
10220205

Supplemental Content

Loading ...
Support Center